Results

Total Results: 406 records

Showing results for "company".

41. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - The company has reported plans to submit global regulatory filings for secukinumab for treating AS … The company is preparing U.S. … intolerant to or have had an inadequate response to NSAIDs, DMARDs, or TNF inhibitor therapy.7 The company … (FDA) approved secukinumab for treating adults with moderate-to-severe plaque psoriasis, and the company … The company has also announced plans for regulatory submissions for an ankylosing spondylitis (AS)

42. Horizon Scanning Protocol and Operations Manual September 2015 Revision (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
    September 01, 2015 - For example, one company may cease development while another company proceeds to market. … quotation marks exactly as issued by study authors from meeting abstracts, published articles, or company … rules as a condition of employment that prohibit ownership of any drug or biotechnology or device company … Company mergers that affect product development (product development may be delayed or halted altogether … Company selling of R&D rights for a product 6.

43. Horizon Scanning Protocol and Operations Manual September 2015 Revision (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
    September 01, 2015 - For example, one company may cease development while another company proceeds to market. … quotation marks exactly as issued by study authors from meeting abstracts, published articles, or company … rules as a condition of employment that prohibit ownership of any drug or biotechnology or device company … Company mergers that affect product development (product development may be delayed or halted altogether … Company selling of R&D rights for a product 6.

44. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - The company has indicated that it will submit premarket approval application to FDA in 2014. … The company has two introductory pricing programs to support diffusion that provide the initial 14 … To aid diffusion, the company is offering special pricing programs in which patients can receive a … The company had a limited distribution system, posing a major barrier to diffusion.34,35 Patients’ … New York (NY): The New York Times Company; 2012 Jul 17 [accessed 2013 Feb 1]. [3 p].

45. Functional-Limitations-Horizon-Scan-High-Impact-1306 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/functional-limitations-horizon-scan-high-impact-1306.pdf
    June 01, 2013 - The company expected to register the ReWalk-P system for personal use with FDA by the end of 2013; … The company submitted a biologics license application (BLA) to FDA in December 2011.64 However, in … indicated about $10 million in sales; the company stated that about 40% of physicians it targeted … The company estimates the battery life for this device to be 3 hours.103 Clinical trials: ReWalk … New York (NY): Fast Company; 2012 Mar 19 [accessed 2012 Mar 30]. [8 p].

46. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - An intranasal formulation is also offered without a prescription on the Internet by a company in Boise … formulation prepared by a compounding pharmacy or may be procuring it from an overseas pharmaceutical company … intranasal oxytocin 30 mL spray is available without prescription on the Internet from at least one company

47. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1306.pdf
    July 01, 2013 - The company has two introductory pricing programs to support diffusion that provide the initial 14- … The company has not indicated when it will seek FDA marketing approval. … To aid diffusion, the company is offering special pricing programs in which patients can receive a … To aid diffusion, the company is offering special pricing programs in which patients can receive a … New York (NY): The New York Times Company; 2012 Jul 17 [accessed 2013 Feb 1]. [3 p].

48. The AHRQ Evidence-Based Care (EBC) Challenge (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ebc_challenge_faq.pdf
    January 01, 2010 - I work for a large organization or company. Can we brand the materials?

49. Vaginal Birth After Cesarean: Developing and Prioritizing a Future Research Agenda (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/cesarean-birth-future_research.pdf
    August 09, 2012 - Legal/Liability and Hospital Administrators 1 1 1 100% (round 1) 100% (round 2) The Doctors Company … Studies of the factors shaping health system administrator & liability company attitudes and decisionmaking … will conduct a series of interviews with key stakeholders - including medical liability and insurance company … will conduct a series of interviews with key stakeholders - including medical liability and insurance company … Studies of the factors shaping HEALTH SYSTEM ADMINISTRATOR & LIABILITY COMPANY attitudes and decision-making

50. Cell-Free-Dna-Appendix-C-Prepub-Final (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-appendix-c-prepub-final.xlsx
    January 01, 2025 - Fan): No Two primary academic coauthors were employees of the company developing the intervention used … Notable concerns There is notable concern due to the academic authors involvement with the company that … is described; company is one of multiple funders listed. … These authors are employees of the company that would benefit from the technology being evaluated, and … As a company developing cancer screening technologies, it has an interest in the results.

51. Cell-Free-Dna-Final-App-C (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-final-app-c.xlsx
    January 01, 2025 - Fan): No Two primary academic coauthors were employees of the company developing the intervention used … Notable concerns There is notable concern due to the academic authors involvement with the company that … is described; company is one of multiple funders listed. … These authors are employees of the company that would benefit from the technology being evaluated, and … As a company developing cancer screening technologies, it has an interest in the results.

52. Using Collaborative Platforms for Communities of Practice (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/grama.pdf
    May 29, 2025 - And then we had to figure out how do we pay a company that’s never done really business with the government

53. Disposition of Comments Report for Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-liver-metastases-therapies_disposition-comments.pdf
    December 11, 2012 - of medical devices is shorter than the cycle of clinical trial and approval; by the time a device company

54. Diabetes Mellitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1306.pdf
    January 01, 2016 - The company resubmitted an NDA to FDA, and the new Prescription Drug User Fee Act date is slated for … The company met with FDA in June 2012, and based on the outcome of that meeting, declared intentions … San Diego (CA): Eli Lilly and Company; 2011 June 24 [accessed 2013 Jun 12]. [4 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Nov 8 [accessed 2011 Nov 11]. [3 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Aug 10 [accessed 2011 Aug 18]. [3 p].

55. Migraine Protocol-Appendix 20111103 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine_protocol-appendix_20111103.pdf
    November 03, 2011 - Elan Pharmaceuticals Eli Lilly and Company Endo Pharmaceuticals EUROHEAD GlaxoSmithKline HaEmek … practice investigating the effectiveness of acupuncture against migraine ClinicalStudyResult.org Company

56. S3 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s3.pdf
    October 01, 2007 - Section of Clinical Epidemi- ology, my colleagues and I received many visits from phar- maceutical company

57. Crosscutting-Horizon-Scan-High-Impact-1506 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - The company received FDA clearance for the monitoring device in March 2010 and for the ingestible sensor … The company is working with selected pharmaceutical manufacturers to choose medications for sensor … adverse events related to the device, of which three were skin rashes and one was nausea.7 The company … In August 2010, the company received CE mark to market the complete system in the European Union.14 … The company announced collaborations with Novartis International AG (Basel, Switzerland) and Otsuka

58. Crosscutting-Horizon-Scan-High-Impact-1412 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - The company received FDA marketing clearance for the monitoring device in March 2010 and for the … The company is working with selected pharmaceutical manufacturers to choose medications for sensor … events related to the device, of which three were skin rashes and 8 one was nausea.28 The company … In August 2010, the company received Conformité Européene (CE) mark approval to market the complete … system in the European Union.35 The company announced collaborations with Novartis International AG

59. Untitled (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/autism-medical-update_research-protocol.pdf
    February 16, 2016 - Medications Addressed in Recent RCTs Including Children with ASD Drug   Company     Anticonvulsants   …   Otsuka  America  Pharmaceutical  Inc.,  Tokyo,  Japan   Olanzapine  (Zyprexa®)   Eli  Lilly  and  Company … ,  Indianapolis,  IN   Olanzapine/Fluoxetine  (Symbyax®)   Eli  Lilly  and  Company,  Indianapolis,   … NSAID,  antihypertensive,  non-­SSRI  antidepressant  )   Atomoxetine  (Strattera®)   Eli  Lilly  and  Company

60. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/dementia_hi_impact.pdf
    January 01, 2012 - would be more willing to approve the agent once the training program was created. 7 According to a company … Indianapolis (IN): Eli Lilly and Company; 2011 Apr 18 [accessed 2011 May 12]. [10 p]. … Indianapolis (IN): Eli Lilly and Company; [accessed 2011 Nov 7]. [1 p].